Ludwig Huber was named compliance fellow for the life sciences and chemical analysis division of Agilent Technologies. His duties will include helping the company identify and evaluate compliance-related initiatives for pharmaceutical laboratory customers. Huber has been at Agilent and parent Hewlett Packard since 1978.
Daniel Keesman, co-CEO and chief operating officer, and Martin Hollenhorst, co-CEO and chief financial officer, as well as all three members of the supervisory board of Lion Bioscience — Jurgen Dormann, Klaus Pohle, and Richard Roy — have resigned. Thure Etzold, managing director for Lion Bioscience UK, and Joseph Donahue, chief business officer for Lion Bioscience in North America, have been appointed as co-CEOs. (see brief, p.9)
William Knight has been appointed as the new chief financial officer of Bruker BioSciences, effective Oct. 25. Before joining Bruker, Knight was chief financial officer of Anika Therapeutics, a medical device company based in Woburn, Mass. Prior to that, Knight was chief financial officer for Zykos, NMT Medical, and Zoll Medical.
David Hoffmeister has become CFO and senior vice president of Invitrogen, succeeding Eric Winzer, the Carlsbad, Calif.-based company said this week. He joins the company from McKinsey, where he was a senior partner. Winzer will remain part of the Invitrogen executive team.
Tim Kish, vice president and CFO of Illumina, will resign in the second quarter of 2005 to move back to the East Coast. He will continue to serve in his role as CFO while the San Diego-based firm initiates a search for his successor.